newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports Third Quarter 2021 Financial Results

Closing of the Sale of a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A Completion of the Clinical Phase of the Phase 1 Multi-A